ELEVAI Labs Inc
NASDAQ:ELAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (15.6), the stock would be worth $-295.82 (9 092% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | $3.29 |
0%
|
| Industry Average | 15.6 | $-295.82 |
-9 092%
|
| Country Average | 16.7 | $-316.67 |
-9 725%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| US |
E
|
ELEVAI Labs Inc
NASDAQ:ELAB
|
6.4m USD | -0.2 | -0.3 | |
| US |
|
Kenvue Inc
NYSE:KVUE
|
33.1B USD | 18.1 | 22.6 | |
| KR |
A
|
APR Co Ltd
KRX:278470
|
15.3T KRW | 44.4 | 53.2 | |
| BR |
|
Natura &Co Holding SA
OTC:NTCOY
|
7.7B USD | -36.9 | -4.4 | |
| KY |
H
|
Herbalife Ltd
XMUN:HOO
|
4.7B EUR | 21.3 | 24 | |
| CN |
M
|
Mao Geping Cosmetics Co Ltd
HKEX:1318
|
38.3B HKD | 25.2 | 27.9 | |
| KR |
d
|
d'Alba Global Co Ltd
KRX:483650
|
2.5T KRW | 144.9 | 159.2 | |
| CN |
|
Runben Biotechnology Co Ltd
SSE:603193
|
10.1B CNY | 34.1 | 33.2 | |
| IN |
H
|
Honasa Consumer Ltd
NSE:HONASA
|
114.4B INR | 88.8 | 73.5 | |
| ID |
|
Industri Jamu dan Farmasi Sido Muncul Tbk PT
IDX:SIDO
|
14.9T IDR | 11.5 | 12.1 | |
| IL |
O
|
Oddity Tech Ltd
NASDAQ:ODD
|
891.3m USD | 12 | 8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 11.7 |
| Median | 16.7 |
| 70th Percentile | 23.6 |
| Max | 3 178 983.5 |
Other Multiples
ELEVAI Labs Inc
Glance View
ELEVAI Labs Inc is a US-based company operating in Personal Care Products industry. The company is headquartered in Newport Beach, California. The company went IPO on 2023-11-21. Elevai Labs, Inc. is a physician-dispensed skincare company. The firm conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. The company produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare products. The company has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.
